MFN2 and diabetic cardiomyopathy: Rocha, A. G., and their team discovered that delivering a Mitofusin 2 (MFN2) agonist using the mitochondria-targeted peptide SS-31 restores mitochondrial fusion in diabetic cardiomyopathy (fission/fusion ratio decreased by 60%), resulting in a doubled mPTP opening threshold (80).